Treatment of hepatitis C: Perspectives

Medecine et Maladies Infectieuses

Volumn 44, Issue 10, 2014, Pages 449-454

  Pol, S ^a   Corouge, M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Direct acting antiviral drugs; Hepatitis C virus; Polymerase inhibitor; Protease inhibitor; Replication complex inhibitor

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; BOCEPREVIR; CYCLOPHILIN INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A POLYMERASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B POLYMERASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL ACTIVITY; BONE MARROW HYPOPLASIA; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; FLU LIKE SYNDROME; GENOTYPE; HEALTH CARE ACCESS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTELLECTUAL IMPAIRMENT; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROCOGNITIVE DISORDER; OUTCOME ASSESSMENT; PILL; PRACTICE GUIDELINE; PRESCRIPTION; PRURITUS; RASH; RELAPSE; REVIEW; SARCOIDOSIS; SKIN DISEASE; THROMBOCYTE COUNT; THYROID DISEASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TUBERCULOSIS; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS REPLICATION; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; PROTEASE INHIBITORS;

EID: 84908214613     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.07.015     Document Type: Review

References (52)

1. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
2. Omland L.H., Krarup H., Jepsen P., Georgsen J., Harritshoj L.H., Riisom K., et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010, 53(1):36-42.
3. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48(1):148-162.
4. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011, 55(2):245-264.
5. Hermine O., Lefrère F., Bronowicki J.P., et al. Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347(2):89-94.
6. Fontaine H., Chaix M.L., Lagneau J.L., et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000, 356:41.
7. Mchutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
8. Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., de Knegt R.J., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147(10):677-684.
9. Mallet V., Gilgenkrantz H., Serpaggi J., Verkarre V., Vallet-Pichard A., Fontaine F., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008, 149(6):399-403.
10. Lee M.H., Yang H.I., Lu S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012, 206(4):469-477.
11. Berenguer J., Rodríguez E., Miralles P., Von Wichmann M.A., López-Aldeguer J., Mallolas J., et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012, 55(5):728-736.
12. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5(6):453-463.
13. Buhler S., Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012, 32(suppl.):16-19.
14. Yang P.L., Gao M., Lin K., Liu Q., Villareal V.A. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011, 1(6):607-616.
15. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
16. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial. Lancet 2011, 376:705-716.
17. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
18. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
19. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
20. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
21. Cacoub P., Bourlière M., Lübbe J., Dupin N., Buggish P., Dusheiko G., et al. Dermatological adverse effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012, 56(2):455-463.
22. Leroy V., Serfaty L., Bourlière M., Bronowicki J.-P., Delasalles P., Pariente A., et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guideline by the French association for the study of the Liver. Liver Int 2012, 32:1477-1492.
23. Poordad F., Lawitz E., Reddy K.R., Afdhal N.H., Hézode C., Zeuzem S., et al. Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic HCV genotype 1 infection-a randomized trial. Gastroenterology 2013, 145(5):1035-1044. [e5. Epub 2013 Aug 4]. 10.1053/j.gastro.2013.07.051.
24. Pol S. HCV, Ribavirin, and anemia: a new dawn. Gastroenterology 2013, 145(5):930-933. [Epub 2013 Sep 20]. 10.1053/j.gastro.2013.09.036.
25. Bruno S., Vierling J.M., Esteban R., Nyberg L.M., Tanno H., Goodman Z., et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013, 58:479-487.
26. Bronowicki J.P., Davis M., Flamm S., Gordon S., Lawitz E., Yoshida E., et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)+PR: the PROVIDE study interim results. J Hepatol 2012, 56(Suppl. 2):S6.
27. Vierling J.M., Zeuzem S., Poordad F., et al. Safety and efficacy of boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials. J Hepatol 2013, 58:S576.
28. Gomez E.V., Rodriguez Y.S., Bertot L.C., Gonzalez A.T., Perez Y.M., Soler E.A., et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol 2013, 58:434-444.
29. Alazawi W., Cunningham M., Dearden J., Foster G.R. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010, 32:344-355.
30. Sangiovanni A., Prati G.M., Fasani P., Ronchi G., Romeo R., Manini M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006, 43:1303-1310.
31. Bruno S., Zuin M., Crosignani A., Rossi S., Zadra F., Roffi L., et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009, 104:1147-1158.
32. Salmon D., Arvieux C., Bourlière M., Cacoub M., Halfon P., Lacome K., et al. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. Liver Int 2014, 34(6):869-889.
33. Hézode C., Fontaine H., Dorival C., Larrey D., Zoulim F., Canva V., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013, 59(3):434-441. [Epub 2013 May 10]. 10.1016/j.jhep.2013.04.035.
34. Burger D., Back D., Buggish P., Buti M., Craxi A., Foster G., et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013, 58(4):792-800.
35. Hezode C., Fontaine H., Dorival C., Zoulim F., Larrey D., Canva V., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterol 2014, 147(1):132-142.
36. Roomer R., Hansen B.E., Janssen H.L.A., de Knegt R.J. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010, 52:1225-1231.
37. Kowdley K.V., Lawitz E., Crespo I., Hassanein T., Davis M.N., Demicco M., et al. Sofosbuvir, an NS5 nucleotide polymerase inhibitor, with peginterferon alfa-2a and ribavirin intreatment-naïve patients with hepatitis C genotypes 1, 4, and 6 infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial. Lancet 2013, [doi:pii: S0140-6736(13)60247-0. 10.1016/S0140-6736(13)60247-0].
38. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887.
39. Gane E.J., Roberts S.K., Stedman C.A., Angus P.W., Ritchie B., Elston R., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
40. Pol S., Ghalib R.H., Rustgi V.K., Martorell C., Everson G.T., Tatum H.A., et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012, 12671-12677.
41. Zeuzem S., Asselah T., Angus P.W., Zarski J.P., Larrey D., Mullhaupt B., et al. Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011, 141(6):2047-2055.
42. Lenz O., Vijgen L., Berke J.M., Cummings M.D., Fevery B., Peeters M., et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013, 58(3):445-451. [Epub 2012]. 10.1016/j.jhep.2012.10.028.
43. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Eng J Med 2012, 366(3):216-224.
44. Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svarovskaia E., Symonds W.T., et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368(1):34-45.
45. Poordad F., Lawitz E., Kowdley K.V., Cohen D.E., Podsadecki T., Siggelkow S., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013, 368(1):45-55.
46. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370(3):211-221. [16]. 10.1056/NEJMoa1306218.
47. Kowdley K.V., Lawitz E., Poordad F., Cohen D.E., Nelson D.R., Zeuzem S., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014, 370(3):222-232. [16]. 10.1056/NEJMoa1306227.
48. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370(21):1973-1982.
49. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Copper C., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370(21):1983-1992.
50. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Eng J Med 2014, 370(20):1889-1898.
51. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Eng J Med 2014, 370(16):1483-1493.
52. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Eng J Med 2014, 370(20):1879-1888.